Skip to main content
Journal cover image

First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.

Publication ,  Journal Article
Alexander, JH; Yang, H; Becker, RC; Kodama, K; Goodman, S; Dyke, CK; Kleiman, NS; Hochman, JS; Berger, PB; Cohen, EA; Lincoff, AM; Burton, JR ...
Published in: J Thromb Haemost
March 2005

BACKGROUND: Unfractionated heparin is widely used in patients with non-ST-elevation acute coronary syndromes but has important limitations. Anticoagulants with predictable kinetics and anticoagulant effects, better efficacy, and greater safety are needed. OBJECTIVE: To investigate the efficacy and safety of a direct, selective factor Xa inhibitor, DX-9065a (Daiichi Pharmaceuticals LTD, Inc.) compared with heparin, in patients with non-ST-elevation acute coronary syndromes. PATIENTS AND METHODS: Patients (n = 402) from the USA, Canada, and Japan were randomized to blinded, weight-adjusted heparin, low-dose DX-9065a, or high-dose DX-9065a. RESULTS: The primary efficacy endpoint of death, myocardial infarction, urgent revascularization, or ischemia on continuous ST-segment monitoring occurred in 33.6%, 34.3%, and 31.3% of patients assigned to heparin, low-dose DX-9065a, and high-dose DX-9065a (P = 0.91 for heparin vs. combined DX-9065a). The composite of death, myocardial infarction, or urgent revascularization occurred in 19.5%, 19.3%, and 11.9% (P = 0.125 for heparin vs. high-dose DX-9065a) of patients; major or minor bleeding occurred in 7.7%, 4.2%, and 7.0% of patients; and major bleeding in 3.3%, 0.8%, and 0.9% of patients. Higher concentrations of DX-9065a were associated with a lower likelihood of ischemic events (P = 0.03) and a non-significant tendency toward a higher likelihood of major bleeding (P = 0.32). CONCLUSIONS: In this small phase II trial, there was a non-significant tendency toward a reduction in ischemic events and bleeding with DX-9065a compared with heparin in patients with acute coronary syndromes. The absence of an effect on ST-monitor ischemia warrants further investigation. These data provide the rationale for adequately powered studies of DX-9065a in acute coronary syndromes or percutaneous intervention.

Duke Scholars

Published In

J Thromb Haemost

DOI

ISSN

1538-7933

Publication Date

March 2005

Volume

3

Issue

3

Start / End Page

439 / 447

Location

England

Related Subject Headings

  • Serine Endopeptidases
  • Propionates
  • Partial Thromboplastin Time
  • Naphthalenes
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Ischemia
  • Humans
  • Heparin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Alexander, J. H., Yang, H., Becker, R. C., Kodama, K., Goodman, S., Dyke, C. K., … XaNADU-ACS INVESTIGATORS, . (2005). First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost, 3(3), 439–447. https://doi.org/10.1111/j.1538-7836.2004.01081.x
Alexander, J. H., H. Yang, R. C. Becker, K. Kodama, S. Goodman, C. K. Dyke, N. S. Kleiman, et al. “First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.J Thromb Haemost 3, no. 3 (March 2005): 439–47. https://doi.org/10.1111/j.1538-7836.2004.01081.x.
Alexander JH, Yang H, Becker RC, Kodama K, Goodman S, Dyke CK, et al. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost. 2005 Mar;3(3):439–47.
Alexander, J. H., et al. “First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.J Thromb Haemost, vol. 3, no. 3, Mar. 2005, pp. 439–47. Pubmed, doi:10.1111/j.1538-7836.2004.01081.x.
Alexander JH, Yang H, Becker RC, Kodama K, Goodman S, Dyke CK, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Burton JR, Bovill EG, Kawai C, Armstrong PW, Harrington RA, XaNADU-ACS INVESTIGATORS. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost. 2005 Mar;3(3):439–447.
Journal cover image

Published In

J Thromb Haemost

DOI

ISSN

1538-7933

Publication Date

March 2005

Volume

3

Issue

3

Start / End Page

439 / 447

Location

England

Related Subject Headings

  • Serine Endopeptidases
  • Propionates
  • Partial Thromboplastin Time
  • Naphthalenes
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Ischemia
  • Humans
  • Heparin